Journal Home
Search for

Volume 88, Issue 4, Pages 906-910 (October 2007)


View previous. 23 of 62 View next.

Stage I ovarian carcinoma: different clinical pathologic patterns

Liane Deligdisch, M.D.a, Frédérique Pénault-Llorca, M.D., Ph.D.b, Peter Schlosshauer, M.D.a, Albert Altchek, M.D.c, Michele Peiretti, M.D.d, Farr Nezhat, M.D.cCorresponding Author Informationemail address

Received 21 October 2006; received in revised form 22 December 2006; accepted 22 December 2006.

Objective

To analyze clinicopathologic patterns of early ovarian carcinoma.

Design

Retrospective chart and histopathology review.

Setting

Mount Sinai School of Medicine, New York and the Centre Jean Perrin, Clermont Ferrand, France.

Patient(s)

Seventy-six consecutive cases of Fédération Internationale de Gynécologie et d'Obstétrique stage I ovarian carcinoma.

Intervention(s)

Surgical staging.

Main Outcome Measure(s)

Symptomatology, pathology, and histology analysis.

Result(s)

Twenty-two cases (29%) were serous papillary carcinomas and 54 were nonserous carcinomas (71%) (40 endometrioid, 10 clear cell, and 4 mixed endometrioid and clear cell carcinomas). Ninety-eight percent of ovarian endometriosis, 95% of endometrial carcinomas, and 83% of endometrial polyps and hyperplasias were associated with nonserous carcinomas. Most patients with serous papillary carcinoma presented with asymptomatic pelvic masses; patients with nonserous carcinomas presented with pelvic pain or abnormal vaginal bleeding with or without pelvic mass.

Conclusion(s)

Over two thirds of stage I ovarian carcinomas were nonserous, and were diagnosed because of associated symptoms: pelvic pain with endometriosis and/or adnexal masses, or vaginal bleeding from endometrial pathology. Serous papillary carcinomas were often asymptomatic and diagnosed during follow-up evaluations in breast cancer patients. Stage I ovarian carcinoma has different clinical and pathologic patterns than advanced ovarian carcinoma. The risk of ovarian and endometrial malignancy should be taken into consideration during evaluation of patients with endometriosis and breast cancer histories.

a The Mount Sinai School of Medicine, Department of Pathology, New York, New York

b Centre de Lutte Contre le Cancer de la Région Auvergne, Department of Pathology, Clermont-Ferrand, France

c The Mount Sinai School of Medicine, Department of Obstetrics, Gynecology and Reproductive Science, New York, New York

d University of Cagliari, Department of Obstetrics and Gynecology, Cagliari, Italy

Corresponding Author InformationCorrespondence to: Farr Nezhat, M.D., Department of Obstetrics, Gynecology and Reproductive Science, The Mount Sinai School of Medicine, 1176 5th Avenue, 9th floor, Box 1170, New York, NY 10029 (FAX: 212-987-6386).

PII: S0015-0282(07)00067-2

doi:10.1016/j.fertnstert.2006.12.035


View previous. 23 of 62 View next.